Happy New Year EveryoneIt has been a rough ride with TRIL this past year + .
This year may be very different because of the amazing early results that are being released and the several significant steps forward that we have on the roadmap for 2019.
It is biotech so it is risky, but with the story that is developing, I am very optimistic that from these levels, there are multiples to be made.
I wish us all the best.
One way or another, the immuno-oncology story is a very compelling one and if it isn't TRIL or 47...then hopefully someone will crack the nut. For the sake of the sufferers, I hope it to be true. The science is starting to align nicely with that hope.
I have faith in the team that leads TRIL and their careful and 'no-pump' approach is not going to win any marketing awards but it also won't land them in any 'Musk-like' SEC trouble.
Deliberate and careful practices result in a solid and lasting conclusion.
Patience will be rewarded but it could start to move at any time. Now that the tax loss pushdown is over, I think it will start to see a lot more green days.
Best
HnG